Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

T-DXd in HER2+ Gastric Cancer: Managing Neutropenia and Other AEs

September 22nd 2022

Focused discussion on the management of antibody drug conjugate–related adverse events in gastric cancer, with a focus on neutropenia.

First- and Second-Line Treatment Options for HER2+ Gastric Cancer

September 22nd 2022

A broad overview of the treatment armamentarium for patients receiving first- or second-line therapy for HER2+ gastric cancer.

Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers

September 21st 2022

Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.

Incidence and Risk Factors for Biliary Tract Cancers

September 21st 2022

Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.

An Overview on Biliary Tract Cancers

September 21st 2022

Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.

FDA Grants Orphan Drug Designation to ATG-101 for Pancreatic Cancer

September 19th 2022

The FDA has granted an orphan drug designation to the novel PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of patients with pancreatic cancer.

FDA Grants Orphan Drug Designation to Ezurpimtrostat for Cholangiocarcinoma

September 19th 2022

The FDA has granted an orphan drug designation to the novel autophagy/palmitoyl protein thioesterase-1 inhibitor ezurpimtrostat for the treatment of patients with cholangiocarcinoma.

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC

September 19th 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

FDA Grants Orphan Drug Status to SY-5609 for Pancreatic Cancer

September 16th 2022

The FDA has granted an orphan drug designation to the CDK7 inhibitor SY-5609 for use as a potential therapeutic option in patients with relapsed metastatic pancreatic cancer.

Atezolizumab and Bevacizumab TRAEs are Potential Predictors of Favorable Outcomes in HCC

September 16th 2022

Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.

Patient Profile 3: A Patient with HER2+ Gastric Cancer Treated With T-DXd–who Develops Neutropenia

September 15th 2022

Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.

A Brief Review of Ongoing Clinical Trials of ADCs in Breast Cancer

September 15th 2022

Before closing out their discussion on antibody drug conjugate use in breast cancer management, panelists consider ongoing clinical trials in this setting.

Neoadjuvant Nivolumab/Ipilimumab Elicits Promising Pathologic Responses in dMMR Colon Cancer

September 11th 2022

Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC

September 11th 2022

Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.

Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer

September 10th 2022

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

LEAP-002 Trial Misses Primary End Points, But Data Support Role of Lenvatinib Monotherapy as SOC in Frontline HCC

September 10th 2022

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC

September 10th 2022

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

September 10th 2022

Managing AEs With Trastuzumab Emtansine in Breast and Gastric Cancers

September 8th 2022

Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.